Multimodality palliative treatment of 111 In-pentetreotide negative/ 123 I-MIBG positive metastatic carcinoid - a case report

Abstract

Patients with carcinoid tumours frequently present with metastatic disease. There are only a few therapeutic options for these patients, and the main goal of palliative treatment is to reduce symptoms and thus to improve quality of life. Current therapy includes surgical resection, hepatic artery embolisation, chemotherapy and somatostatin analogue treatment; however, all these options have limitations. It seems probable that therapeutic modalities based on radiopharmaceuticals may provide better therapy, not only in relation to symptom reduction but may also improve patient survival.
In this case report we present a 46-year-old woman with a symptomatic carcinoid, who at the time of diagnosis had liver and abdominal lymph node metastases, the primary tumour being located in the terminal ileum. ¹¹¹In-pentetreotide scanning was negative, whereas ¹²³I-MIBG scanning showed high avidity in the tumour tissue. After right hemicolectomy, two courses of ¹³¹I-MIBG treatment were given (12.95 GBq and 12 GBq, respectively). After the second dose of ¹³¹I-MIBG temporary pancytopenia was present. Octreotide therapy was given empirically only for a short time and was stopped because of drug intolerance. The patient underwent tricuspid and pulmonary valve replacement because of her carcinoid heart disease, followed by two courses of embolisation of liver metastases. While ¹³¹I-MIBG therapy reduced the patient’s symptoms of flushing and diarrhoea, there has not yet been any effect on tumour response or 5-HIAA production. This case illustrates the multimodality and multidisciplinary approach to such patients.